

Data Sharing Statement

Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ -Secretase Inhibitor for Desmoid Tumors. N Engl J Med. DOI: 10.1056/NEJMoa2210140.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	—
Additional information about data	—
How or where can the data be obtained?	SpringWorks Therapeutics is committed to data transparency and sharing data to further research while maintaining the privacy and confidentiality of research participants. Pertinent patient-level data from completed registrational clinical trials will be made available by SpringWorks to qualified researchers upon approval of reasonable requests following de-identification/anonymization pursuant to applicable law. Requests for data must be sent to medinfo@springworkstx.com .
When will data availability begin?	After publication and marketing authorization in US (or development discontinued), subject to review
When will data availability end?	There is no end date for eligibility to submit a data sharing request
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—

Any other restrictions?	—
Additional information	—

This statement was posted on March 9, 2023, at NEJM.org.